[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-377794-105":59,"doc-detail-377794-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","urinary-blacat1-as-a-non-invasive-biomarker-for-bladder-cancer","Urinary BLACAT1 as a Non-Invasive Biomarker for Bladder Cancer","","Bladder cancer ranks among the most common malignancies worldwide and carries a high recurrence risk, with many non-muscle-invasive cases progressing rapidly to muscle-invasive disease and metastasis. Limited available biomarkers further constrain accurate diagnosis and prognosis. This study evaluates urinary lncRNA BLACAT1 as a non-invasive diagnostic and prognostic biomarker, assessing its expression and clinical relevance across bladder cancer stages to distinguish disease progression and patient outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/urinary-blacat1-as-a-non-invasive-biomarker-for-bladder-cancer/377794/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/urinary-blacat1-as-a-non-invasive-biomarker-for-bladder-cancer/377794.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in bladder cancer diagnosis and prognosis?","Question",{"text":113,"@type":114},"It targets the high recurrence and progression of bladder cancer and the lack of sufficient biomarkers for diagnosis and prognostic assessment, aiming to find sensitive and specific non-invasive markers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was urinary BLACAT1 expression measured and compared?",{"text":118,"@type":114},"Urinary BLACAT1 levels were measured using qRT-PCR in 70 bladder cancer patients across TNM grades (T0–T3) and 12 healthy subjects as controls.",{"name":120,"@type":111,"acceptedAnswer":121},"What does higher urinary BLACAT1 indicate about bladder cancer outcomes?",{"text":122,"@type":114},"BLACAT1 is upregulated in invasive stages and its increase correlates with disease progression, suggesting an unfavorable prognosis and supporting its use as a metastatic biomarker.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},377794,1790269320,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Molecular Biology Reports (2023) 50:4339–4345 [https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1033-023-08370-z  \nUrinary BLACAT1 as a non‑invasive biomarker for bladder cancer  \nFathia Z. El Sharkawi1 · Mahmoud El Sabah2 · Hanaa B. Atya1 · Hussein M. Khaled3  \nReceived: 14 October 2022 / Accepted: 2 March 2023 / Published online: 20 March 2023 © The Author(s) 2023  \nAbstract  \nBackground Bladder cancer (BC) is recorded as the fifth most common cancer worldwide with high morbidity and mortality. The most urgent problem in BCs is the high recurrence rate as two-thirds of non-muscle-invasive bladder cancer (NMIBC) will develop into muscle-invasive bladder cancer (MIBC), which retains a feature of rapid progress and metastasis. In addition, only a limited number of biomarkers are available for diagnosing BC compared to other cancers. Hence, finding sensitive and specific biomarkers for predicting the diagnosis and prognosis of patients with BC is critically needed. Therefore, this study aimed to determine the expression and clinical significance of urinary lncRNA BLACAT1 as a non-invasively diagnostic and prognostic biomarker to detect and differentiate BCs stages.  \nMethods and results The expression levels of urinary BLACAT1 were detected by qRT-PCR assay in seventy (70) BC patients with different TNM grades (T0-T3) and twelve (12) healthy subjects as control. BLACAT1 was downregulated in superficial stages (T0 = 0.09 ± 0.02 and T1 = 0.5 ± 0.1) compared to healthy control. Furthermore, in the invasive stages, its levels started to elevate in the T2 stage (1.2 ± 0. 2), and higher levels were detected in the T3 stage with a mean value of (5.2 ± 0.6) . This elevation was positively correlated with disease progression. Therefore, BLACAT1 can differentiate between metastatic and non-metastatic stages of BCs. Furthermore, its predictive values are not like to be influenced by schistosomal infection. Conclusions Upregulation of BLACAT1 in invasive stages predicted an unfavorable prognosis for patients with BCs, as it contributes to the migration and metastasis of BCs. Therefore, we can conclude that urinary BLACAT1 may be considered a non-invasive promising metastatic biomarker for BCs.  \nKeywords BLACAT1 · Bladder cancer · LncRNA · Metastatic marker  \n* Hanaa B. Atya [hanaa.atya@pharm.helwan.edu.eg](hanaa.atya@pharm.helwan.edu.eg)  \nFathia Z. El Sharkawi  \n[Fathia.elsharkawy@pharm.helwan.edu.eg](Fathia.elsharkawy@pharm.helwan.edu.eg)  \nMahmoud El Sabah  \n[mahmoud.elsabah@yahoo.com](mahmoud.elsabah@yahoo.com)  \nHussein M. Khaled  \n[Khaledh@cu.edu.eg](Khaledh@cu.edu.eg)  \n1 Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, P.O. Box 11795, Cairo, Egypt  \n2 Department of Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University, Cairo, Egypt  \n3 National Cancer Institute, Cairo University, Cairo, Egypt  \nIntroduction  \nMalignant bladder cancers are the greatest common tumorsin the genitourinary system. Globally, Bladder cancer (BC) alarms around 550,000 new cases annually and its frequency is continually increasing [1] . BC is divided into two subgroups: non-muscle invasive bladder cancer (NMIBC), an early stage of cancer (stages T0 to T1), and muscle-invasive bladder cancer (MIBC), which is more destructive (stages T2 to T4) . At diagnosis, the majority of BCs are NMIBC [2 , 3] . Early diagnosis and handling of tumorous lesions are assumed to be essential for dropping the risk of relapse and improving the prognosis of NMIBC [4] . Regardless of enhancements in current clinical management such as surgery, radiation therapy, and chemotherapy, 50–70% of patients are relapsed within the next 5 years [5] . Hence, it is crucial to discover novel molecular markers for diagnosis atthe primary stage and detect effective therapeutic marks for improving the survival rate of BC patients.  \nLong non-coding RNAs (lncRNAs) are a subgroup of RNAs that have above 200 nuc","cbCaij3Z0LCcIq2B","https://ap.wps.com/l/cbCaij3Z0LCcIq2B","pdf",821427,"English","# Abstract\n# Methods and results\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What problem does the study address in bladder cancer diagnosis and prognosis?\",\"answer\":\"It targets the high recurrence and progression of bladder cancer and the lack of sufficient biomarkers for diagnosis and prognostic assessment, aiming to find sensitive and specific non-invasive markers.\"},{\"question\":\"How was urinary BLACAT1 expression measured and compared?\",\"answer\":\"Urinary BLACAT1 levels were measured using qRT-PCR in 70 bladder cancer patients across TNM grades (T0–T3) and 12 healthy subjects as controls.\"},{\"question\":\"What does higher urinary BLACAT1 indicate about bladder cancer outcomes?\",\"answer\":\"BLACAT1 is upregulated in invasive stages and its increase correlates with disease progression, suggesting an unfavorable prognosis and supporting its use as a metastatic biomarker.\"}]","Urinary BLACAT1 as a Non-Invasive Biomarker for Bladder Cancer | PDF",1790227184,18]